Table Of Contents

1. Market Context & Strategic Relevance

 1.1 Opening Context (Why the market matters)

 1.1.1 Why This Market Is Gaining Strategic Attention

     1.1.2 Business Decisions This Report Supports

 1.2 Scope

     1.3 Research & Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Drug Type

  2.3.2 Market Size By Therapeutic Area

  2.3.3 Market Size By Route of Administration

 2.3.4 Market Size By End Use

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

3.4.1. Drug Data, Compound Libraries & Research Resource Providers

3.4.2. Drug Repurposing Platform, Biotechnology & Pharmaceutical Companies

3.4.3. CROs, Clinical Research & Drug Development Service Providers

3.4.4. Pharmaceutical Companies, Hospitals, Academic Institutions & Research Organizations

 3.5 Industry Life Cycle Assessment

4. Statistical Insights & Trends Reporting

4.1 Drug Development & Repurposing Performance Statistics

 4.1.1 Average Time Required for Drug Repurposing From Candidate Identification to Regulatory Approval (Years)

 4.1.2 Average Reduction in Drug Development Time Through Repurposing (%)

 4.1.3 Average Drug Repurposing Approval Success Rate (%)

 4.1.4 Average Reduction in Preclinical Development Requirements Through Drug Repurposing (%)

 4.1.5 Average Reduction in Drug Development Costs Through Repurposing (%)

4.2 Clinical Development & Trial Performance Metrics

 4.2.1 Average Number of Clinical Trials Conducted for Repurposed Drug Candidates

 4.2.2 Average Clinical Trial Success Rate of Repurposed Drug Candidates (%)

 4.2.3 Average Patient Enrollment in Drug Repurposing Clinical Trials

 4.2.4 Average Clinical Development Duration for Repurposed Drugs (Months/Years)

 4.2.5 Average Reduction in Phase I Development Time Through Drug Repurposing (%)

4.3 Therapeutic Efficacy & Safety Statistics

 4.3.1 Average Therapeutic Efficacy Rate of Repurposed Drugs (%)

 4.3.2 Average Reduction in Treatment-Related Adverse Events Through Repurposed Drugs (%)

 4.3.3 Average Safety Profile Validation Rate of Previously Approved Drugs (%)

 4.3.4 Average Improvement in Patient Treatment Outcomes Through Drug Repurposing (%)

 4.3.5 Average Reduction in Drug Development Risk Through Use of Established Safety Data (%)

4.4 Drug Discovery & Data Analytics Performance Metrics

 4.4.1 Average Number of Existing Drugs Screened for New Therapeutic Indications

 4.4.2 Average Drug–Disease Associations Identified Through Computational Repurposing Platforms

 4.4.3 Average Improvement in Drug Candidate Identification Efficiency Through AI and Machine Learning (%)

 4.4.4 Average Reduction in Drug Screening Time Through Computational Repurposing (%)

 4.4.5 Average Accuracy of Drug Repurposing Prediction Models (%)

5. Drug Repurposing Market Segmental Analysis & Forecast, By Drug Type, 2022–2035, Value (USD Billion)

5.1 Introduction

 5.2 Small Molecules

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.3 Biologics

6. Drug Repurposing Market Segmental Analysis & Forecast, By Therapeutic Area, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 Oncology

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Neurology and CNS Disorders

 6.4 Infectious Diseases

 6.5 Cardiovascular Diseases

 6.6 Metabolic Disorders

 6.7 Other Therapeutic Areas

7. Drug Repurposing Market Segmental Analysis & Forecast, By Route of Administration, 2022–2035, Value (USD Billion)

    7.1 Introduction

 7.2 Oral

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Intravenous

 7.4 Other Routes of Administration

8. Drug Repurposing Market Segmental Analysis & Forecast, By End Use, 2022–2035, Value (USD Billion)

    8.1 Introduction

 8.2 Pharmaceutical and Biopharmaceutical Companies

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2022–2035

 8.3 Contract Research Organizations (CROs)

 8.4 Other End Uses

9. Drug Repurposing Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 Drug Repurposing Market Size & Forecast, By Drug Type, 2022–2035

 9.2.3 Drug Repurposing Market Size & Forecast, By Therapeutic Area, 2022–2035

 9.2.4 Drug Repurposing Market Size & Forecast, By Route of Administration, 2022–2035

 9.2.5 Drug Repurposing Market Size & Forecast, By End Use, 2022–2035

 9.2.6 Drug Repurposing Market Size & Forecast, By Country, 2022–2035

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 Drug Repurposing Market Size & Forecast, By Drug Type, 2022–2035

 9.3.3 Drug Repurposing Market Size & Forecast, By Therapeutic Area, 2022–2035

 9.3.4 Drug Repurposing Market Size & Forecast, By Route of Administration, 2022–2035

 9.3.5 Drug Repurposing Market Size & Forecast, By End Use, 2022–2035

 9.3.6 Drug Repurposing Market Size & Forecast, By Country, 2022–2035

  9.3.6.1 Germany

  9.3.6.2 UK

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 Drug Repurposing Market Size & Forecast, By Drug Type, 2022–2035

 9.4.3 Drug Repurposing Market Size & Forecast, By Therapeutic Area, 2022–2035

 9.4.4 Drug Repurposing Market Size & Forecast, By Route of Administration, 2022–2035

 9.4.5 Drug Repurposing Market Size & Forecast, By End Use, 2022–2035

 9.4.6 Drug Repurposing Market Size & Forecast, By Country, 2022–2035

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 Drug Repurposing Market Size & Forecast, By Drug Type, 2022–2035

 9.5.3 Drug Repurposing Market Size & Forecast, By Therapeutic Area, 2022–2035

 9.5.4 Drug Repurposing Market Size & Forecast, By Route of Administration, 2022–2035

 9.5.5 Drug Repurposing Market Size & Forecast, By End Use, 2022–2035

 9.5.6 Drug Repurposing Market Size & Forecast, By Country, 2022–2035

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 Drug Repurposing Market Size & Forecast, By Drug Type, 2022–2035

 9.6.3 Drug Repurposing Market Size & Forecast, By Therapeutic Area, 2022–2035

 9.6.4 Drug Repurposing Market Size & Forecast, By Route of Administration, 2022–2035

 9.6.5 Drug Repurposing Market Size & Forecast, By End Use, 2022–2035

 9.6.6 Drug Repurposing Market Size & Forecast, By Country, 2022–2035

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 South Africa

  9.6.6.5 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Year-Wise Strategies & Development, 2022–2026

 10.3 Market Share Analysis, 2025

 10.4 Product/Service & Application Benchmarking

  10.4.1 Product/Service Specifications & Features By Key Players

  10.4.2 Product/Service Heatmap By Key Players

  10.4.3 Application Heatmap By Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

 10.6.1 AbbVie Inc.

  10.6.1.1 Company Overview & Snapshot

  10.6.1.2 Product/Service Portfolio

  10.6.1.3 Key Company Financials

         10.6.1.4 Geographical Presence

  10.6.1.5 SWOT Analysis

10.6.2 Amgen Inc.

10.6.3 Boehringer Ingelheim International GmbH

10.6.4 Eli Lilly and Company

10.6.5 GSK plc

10.6.6 Novartis AG

10.6.7 Pfizer Inc.

10.6.8 Sanofi S.A.

10.6.9 AstraZeneca plc

10.6.10 Johnson & Johnson

10.6.11 Takeda Pharmaceutical Company Limited

10.6.12 Bristol Myers Squibb Company

10.6.13 Roche Holding AG

10.6.14 Biogen Inc.

10.6.15 Recursion Pharmaceuticals, Inc.

10.6.16 Evotec SE

10.6.17 Melior Discovery, Inc.

10.6.18 SOM Biotech S.L.

10.6.19 Every Cure

10.6.20 NovaLead Pharma Pvt. Ltd.

11. Analyst Recommendations

 11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List Of Tables

 14.2 List Of Figures